25
Aug
2017

Adamas Wins Parkinson’s Drug Approval, Genmab Soars, Amgen Defends PCSK9 Price

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK
Recursion Scoops up Rival, Servier’s Brain Cancer Win, & Cell Therapy for Solid Tumors
PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100